Apple Tree Partners

Developer of a focal non-viral gene therapy designed to overcome the limitations of viral-based gene therapy. The company's therapy uses synthetic biology and engineered gene circuits to make covalently closed and circular DNA molecules, thereby enabling patients to have access to new gene therapies which have been beset by safety issues, technical obstacles, and manufacturing cost challenges that have so far restricted their use to a small subset of diseases.

Narus Health, Inc. provides palliative care services to patients facing a life-limiting illness. The company assists in care coordination, provides in-home care and real time assessments, presents evidence-based knowledge of treatment options, and empowers patients to make informed decisions about their health and lifestyle. It serves patients and families, health plans, large employers, physicians, and clinicians. The company was founded in 2015 and is based in Nashville, Tennessee.

Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Limelight Bio is a multi-platform, multi-disease focused biopharmaceutical company expanding the limits of gene therapy. The company is developing novel gene therapies that greatly expand the utility of clinically-validated AAV vectors to enable the treatment of debilitating inherited diseases that cannot be addressed by current technologies; such as those caused by mutations in large genes and autosomal dominant inheritance patterns. Limelight Bio's proprietary technologies are designed to overcome limitations of currently available viral-based treatments to address a wider range of diseases. It was founded in 2016 and is headquartered in Philadelphia, Pennsylvania, United States.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform called SynRGY. By deploying SynRGY technology, the company aims to design novel treatments that prevent the occurrence of drug resistance and create solutions that enhance the effectiveness of many immuno-oncology regimens.

Cyrano Sciences, is focused on providing chemical and biological sensors and software solutions.

NEREID THERAPEUTICS INC. focuses in the discovery of small molecules that can modulate protein interactions found in disease states using liquid-liquid phase separation. The company is based in Cambridge, Massachusetts.

Syntimmune, Inc. is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. The company was founded in 2013 and is based in Boston, Massachusetts. As of November 2, 2018, Syntimmune, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Syntimmune, Inc. is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. The company was founded in 2013 and is based in Boston, Massachusetts. As of November 2, 2018, Syntimmune, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Limelight Bio is a multi-platform, multi-disease focused biopharmaceutical company expanding the limits of gene therapy. The company is developing novel gene therapies that greatly expand the utility of clinically-validated AAV vectors to enable the treatment of debilitating inherited diseases that cannot be addressed by current technologies; such as those caused by mutations in large genes and autosomal dominant inheritance patterns. Limelight Bio's proprietary technologies are designed to overcome limitations of currently available viral-based treatments to address a wider range of diseases. It was founded in 2016 and is headquartered in Philadelphia, Pennsylvania, United States.

NEREID THERAPEUTICS INC. focuses in the discovery of small molecules that can modulate protein interactions found in disease states using liquid-liquid phase separation. The company is based in Cambridge, Massachusetts.

QualDerm Partners provides strategic leadership and practice management services for dermatologists and skin care professionals across the southeastern United States, enabling them to focus more on patients and less on administrative efforts. They foster a practice-centric philosophy, which defines the culture that drives how they manage our business to provide the best care for the patients they serve.

Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira’s portfolio of five product candidates targets significant market opportunities. It was founded in 2010 and headquartered in Menlo Park, California.

Nine Square Therapeutics is discovering new small-molecule therapeutics for degenerative movement disorders including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), as well as non-degenerative disorders such as essential tremor and dyskinesias, by integrating computational chemistry, biophysics, and computational biology into machine-learning-enabled cell profiling platforms for target identification, chemical optimization, and patient stratification. It was founded in 2020 and headquartered in New York, United States.

Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis.

Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis.

Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Gloucester Pharmaceuticals is a biopharmaceutical company owned by [Celgene](/organization/celgene) that acquires clinical-stage oncology drug candidates with the goal of advancing them through regulatory approval and commercialization. Gloucester's first compound, romidepsin, is a late-stage oncology drug candidate that has shown potential activity across a range of hematological malignancies. The Company retains worldwide exclusive rights to romidepsin, an oncology candidate within a new class of anti-cancer agents known as histone deacetylase (HDAC) inhibitors. Preclinical studies suggest that romidepsin is a potent inhibitor of Class I, Class II and Class IV HDACs.

Tendyne Holdings Inc. develops medical device for transcatheter mitral valve replacement, repair, and targeting mitral regurgitation. The company was incorporated in 2010 and is based in Roseville, Minnesota. As of August 2015, Tendyne Holdings Inc. operates as a subsidiary of Abbott Laboratories.

Novus Therapeutics is a pharmaceutical company focusing on the acquisition, development, and commercialization of ear, nose, and throat (ENT) products. The company has two technologies, each of which has the potential to be developed for multiple ENT indications. It was founded in 2004 and headquartered in Irvine, California.

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. The company was founded in 2019 and headquartered in Alberta, Canada.

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Galvanize Therapeutics provides therapeutic products and services and currently operates on stealth mode. The company was founded in 2015 and is headquartered in Menlo Park, California, United States.

Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.

Novus Therapeutics is a pharmaceutical company focusing on the acquisition, development, and commercialization of ear, nose, and throat (ENT) products. The company has two technologies, each of which has the potential to be developed for multiple ENT indications. It was founded in 2004 and headquartered in Irvine, California.

VytronUS, Inc. manufactures and markets cardiac medical devices. VytronUS, Inc. was formerly known as CardionUS, Inc. The company was founded in 2006 and is based in Sunnyvale, California.

Gala Therapeutics is a privately-held medical device company developing disease-modifying therapies to improve survival for patients with pulmonary diseases. Its therapies address the needs of interventional pulmonologists, thoracic surgeons, and physicians who treat a pulmonary disease that enables them to treat their patients better, resulting in a better medical outcome. It was founded in 2015 and is headquartered in Menlo Park, California.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Developer of a focal non-viral gene therapy designed to overcome the limitations of viral-based gene therapy. The company's therapy uses synthetic biology and engineered gene circuits to make covalently closed and circular DNA molecules, thereby enabling patients to have access to new gene therapies which have been beset by safety issues, technical obstacles, and manufacturing cost challenges that have so far restricted their use to a small subset of diseases.

Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis.

Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Elstar Therapeutics Inc. operates as a biotechnology company that develops immunotherapies. The company produces molecules that treat various diseases in oncology and autoimmunity. Elstar Therapeutics Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

VytronUS, Inc. manufactures and markets cardiac medical devices. VytronUS, Inc. was formerly known as CardionUS, Inc. The company was founded in 2006 and is based in Sunnyvale, California.

Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid use disorder. We are dedicated to advancing next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of opioid use disorder faced by patients, healthcare professionals, payers, and society.

Syntimmune, Inc. is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. The company was founded in 2013 and is based in Boston, Massachusetts. As of November 2, 2018, Syntimmune, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally.

Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Syntimmune, Inc. is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. The company was founded in 2013 and is based in Boston, Massachusetts. As of November 2, 2018, Syntimmune, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Novus Therapeutics is a pharmaceutical company focusing on the acquisition, development, and commercialization of ear, nose, and throat (ENT) products. The company has two technologies, each of which has the potential to be developed for multiple ENT indications. It was founded in 2004 and headquartered in Irvine, California.

Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid use disorder. We are dedicated to advancing next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of opioid use disorder faced by patients, healthcare professionals, payers, and society.

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Elstar Therapeutics Inc. operates as a biotechnology company that develops immunotherapies. The company produces molecules that treat various diseases in oncology and autoimmunity. Elstar Therapeutics Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Cure Forward is a healthcare company that specializes in the fields of genomic medicine, consumer healthcare, oncology, and clinical trials. The company helps cancer patients and physicians access advanced treatments in oncology. It was founded in 2014 and is headquartered in Boston, Massachusetts.

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. The company was founded in 2019 and headquartered in Alberta, Canada.

Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.

Cerecor, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of prescription pharmaceuticals. The company focuses on human brain and nervous system. Its products include translational medicines, products for cough, and inhibitors for schizophrenia. The company was incorporated in 2011 and is based in Baltimore, Maryland.

Novus Therapeutics is a pharmaceutical company focusing on the acquisition, development, and commercialization of ear, nose, and throat (ENT) products. The company has two technologies, each of which has the potential to be developed for multiple ENT indications. It was founded in 2004 and headquartered in Irvine, California.

ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform called SynRGY. By deploying SynRGY technology, the company aims to design novel treatments that prevent the occurrence of drug resistance and create solutions that enhance the effectiveness of many immuno-oncology regimens.

Adendra is an emerging biotechnology company building on new insights into dendritic cell biology to discover and develop new small molecule and biologic medicines for the treatment of a wide range of cancers and autoimmune diseases.

Gloucester Pharmaceuticals is a biopharmaceutical company owned by [Celgene](/organization/celgene) that acquires clinical-stage oncology drug candidates with the goal of advancing them through regulatory approval and commercialization. Gloucester's first compound, romidepsin, is a late-stage oncology drug candidate that has shown potential activity across a range of hematological malignancies. The Company retains worldwide exclusive rights to romidepsin, an oncology candidate within a new class of anti-cancer agents known as histone deacetylase (HDAC) inhibitors. Preclinical studies suggest that romidepsin is a potent inhibitor of Class I, Class II and Class IV HDACs.